KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Amortizatization of Intangibles (2018 - 2023)

Historic Amortizatization of Intangibles for Esperion Therapeutics (ESPR) over the last 6 years, with Q2 2023 value amounting to $73000.0.

  • Esperion Therapeutics' Amortizatization of Intangibles rose 13668.34% to $73000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $73000.0, marking a year-over-year decrease of 6866.95%. This contributed to the annual value of $412000.0 for FY2023, which is 24767.03% up from last year.
  • Per Esperion Therapeutics' latest filing, its Amortizatization of Intangibles stood at $73000.0 for Q2 2023, which was up 13668.34% from $339000.0 recorded in Q1 2023.
  • In the past 5 years, Esperion Therapeutics' Amortizatization of Intangibles registered a high of $339000.0 during Q1 2023, and its lowest value of -$199000.0 during Q2 2022.
  • Its 5-year average for Amortizatization of Intangibles is $29857.1, with a median of $33000.0 in 2019.
  • As far as peak fluctuations go, Esperion Therapeutics' Amortizatization of Intangibles plummeted by 7894.74% in 2020, and later surged by 226666.67% in 2022.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Amortizatization of Intangibles stood at $60000.0 in 2019, then tumbled by 93.33% to $4000.0 in 2020, then tumbled by 400.0% to -$12000.0 in 2021, then soared by 2266.67% to $260000.0 in 2022, then tumbled by 71.92% to $73000.0 in 2023.
  • Its last three reported values are $73000.0 in Q2 2023, $339000.0 for Q1 2023, and $260000.0 during Q4 2022.